A new vaccine targeted at enabling the disease fighting capability to fight advanced cancer has been trialled in London and Guildford.
Scientists are testing the effectiveness and safety of the vaccine which functions by resembling the natural immune responses made by your body against bacterial and viral infections.
All patients with any solid tumour, regardless of their kind of cancer and tumour genetic profile, are thought to have the potential to reap the benefits of this type of treatment.
The (VAPER) trial is occurring at the National Institute for Health Research (NIHR) Guy’s and St Thomas’ Clinical Research Facility and the NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London (BRC). Other centres at the Surrey Cancer Research Institute (SCRI) at the University of Surrey and the Royal Surrey County Hospital are anticipated to commence patient recruitment later this season.
The first two patients have been vaccinated in a trial that is expected to run for 18-24 months with recruitment of patients currently ongoing.
The purpose of the trial is to determine the great things about the vaccination programme, any side effects associated with it and the impact of the treatment on patients’ standard of living. Scientists hope the results will need them one step nearer to developing a powerful but nontoxic cancer remedy you can use in clinical practice.
The clinical teams are being led by Dr James Spicer, Principal Investigator at the BRC and King’s College London and Professor Hardev Pandha from SCRI.
Dr Spicer said: “The initial feature of the study is the utilization of additional agents to improve the vaccination response. It really is hoped this will abolish the inhibitory aftereffect of regulatory immune cells within the patients’ circulation, that are thought to have limited the potency of previous cancer vaccine approaches.”
Professor Pandha said, “We realize that the disease fighting capability in patients with advanced cancer is supressed, so it is struggling to recognise and kill cancer calls. Within this trial our company is investigating a kind of immunotherapy made to activate your body’s disease fighting capability by administration of any vaccine predicated on fragments of an integral cancer protein.”
The look of the VAPER trial is an all natural progression and development of the results from previous pilot immunotherapy studies and it is supported by data from related trials completed in the united kingdom, USA and in Europe elsewhere.
Candles, a Lincolnshire Registered Charity, has played an essential role in supporting the study like the key pioneering work completed by Professor Eremin at the Lincoln County Hospital and Queen’s Medical Centre, Nottingham and by Professor Farzin Farzaneh, King’s College London. Candles is constantly on the provide funding because of this new VAPER Trial programme also to actively fundraise for the continuation of the study.
If the trial prove successful showing the vaccine is well tolerated, it will be expanded to a larger number of patients to further examine its effectiveness.
Life Sciences Minister George Freeman MP said: “This trial is pushing new boundaries for potential cancer treatments, and brings new expect patients in the fight cancer. The chance of any vaccine to help your body’s disease fighting capability fight advanced cancer highlights the ground-breaking work being delivered by our world-leading life sciences sector, supported through the Government’s continued investment in the National Institute for Health Research.”
Patient research study ï¿½ Miss Kelly Potter
Beckenham resident Kelly Potter, 35, an individual of Guy’s Hospital is on the VAPER trial. She was identified as having stage four cervical cancer in July 2015. She said: “Although I had developed excellent treatment at Guy’s Hospital where in fact the cancer was stabilised, it had spread to spots on my liver and lungs already. So after i was told that I might qualify for this trial, I had been delighted.
“When I browse the leaflet about the VAPER trial it struck me which it seemed a lttle bit of breakthrough which if it worked, maybe it’s a revolution in the treating cancer.
“To participate the trial has changed my entire life for the better. It has been an extremely positive experience and really interesting. Personally i think honoured to be engaged. You have the best treatment anyway at Guy’s but it’s fantastic to participate something that may be ground breaking.
“I had developed my first injection on Tuesday 9th February and also have another seven visits to complete the procedure. They did say there could be flu like symptoms but I haven’t noticed anything yet.
“The way I have already been looked after and treated by the clinical trial staff is exceptional. Everyone says hello, they know my name, they are incredibly caring, you are not simply a person or a number they treat you individually. I cannot thank them enough.
“My expect the near future is to beat the cancer for so long as I could and easily can’t I’ve come to conditions with that. I’d like to be on and inspire others with cancer. I am supporting cancer patients on social media already, telling them what things to expect by sharing my very own activities but ultimately, I’d want to volunteer or benefit a cancer charity.”
Trial for potential new drug that may help disease fighting capability fight cancer